Histiocytic sarcoma (HS) is an extremely rare (<1% of hematologic malignancies) and aggressive neoplasm characterized by malignant proliferation of cells with mature histiocyte/macrophage phenotype. Lymph nodes, skin, GI, spleen, and soft tissues are the most common sites of involvement. Can occur at any age but more common in adults (median age 50-60) with slight male predominance. May develop through transdifferentiation from follicular lymphoma, low-grade B-cell lymphoma, or acute lymphoblastic leukemia. Clinically presents with rapidly growing mass, B symptoms (fever, night sweats, weight loss), and cytopenias. Histologically characterized by CD68+, CD163+, lysozyme+, S100± large pleomorphic cells. Prognosis is generally poor — median survival 6-24 months. On imaging, aggressive, large, heterogeneously enhancing, necrotic mass and/or lymphadenopathy is seen.
Age Range
30-80
Peak Age
55
Gender
Male predominant
Prevalence
Rare
Histiocytic sarcoma develops through malignant transformation of mature tissue histiocytes/macrophages. Two main pathways have been defined: (1) De novo development — malignant transformation of histiocyte precursors through oncogenic mutations (BRAF V600E, RAS, MAPK pathway mutations) and (2) Transdifferentiation — conversion from pre-existing lymphoid neoplasm (follicular lymphoma, DLBCL, ALL) to histiocytic lineage. In transdifferentiation cases, clonal immunoglobulin gene rearrangements shared with the original lymphoid neoplasm have been demonstrated — proving origin from a common precursor cell. Malignant histiocytes exhibit normal histiocyte functions (phagocytosis, cytokine production) at increased levels — hemophagocytosis and cytokine storm (IL-6, TNF-α, IFN-γ) lead to cytopenias and systemic symptoms. On imaging, aggressive, large, heterogeneous mass reflects rapid tumoral growth and necrosis. Heterogeneous enhancement on CT results from coexistence of viable tumoral tissue and necrosis areas. Marked diffusion restriction on DWI reflects dense proliferation of malignant histiocytes. Very intense FDG uptake on PET-CT reflects intense glucose consumption of malignant histiocytes for both phagocytic activity and proliferation.
Rapidly growing, necrotic, very intensely FDG-avid (SUVmax >15-20) large mass or LAP with cytopenias and hemophagocytic syndrome findings is highly characteristic of histiocytic sarcoma.
On contrast-enhanced CT, a large (generally >5 cm), heterogeneously enhancing mass is seen — central necrosis areas are common. In lymph node involvement, large, necrotic, irregularly bordered conglomerate LAP may be seen. Invasion of surrounding structures (vascular, bone) may accompany. Hepatosplenomegaly may be seen if hemophagocytic syndrome accompanies.
Report Sentence
CT demonstrates a large ___mm, heterogeneously enhancing mass/LAP with central necrosis; findings consistent with high-grade malignancy.
On B-mode US, a large, heterogeneous, predominantly hypoechoic mass is seen — necrotic areas may appear anechoic. Hilum is lost. Irregular borders reflect aggressive growth.
Report Sentence
On US, a large, heterogeneous, hypoechoic mass with accompanying necrotic areas is noted.
On Doppler, chaotic peripheral vascularity in the mass — irregular neovascular vessels. Necrotic areas are avascular.
Report Sentence
Doppler demonstrates chaotic peripheral vascularity in the mass with central avascular necrotic areas.
On DWI, viable tumoral areas demonstrate marked diffusion restriction — ADC values generally in 0.5-0.9 × 10⁻³ mm²/s range. Necrotic areas show higher ADC. Heterogeneous ADC map reflects mixed structure of aggressive malignancy.
Report Sentence
On DWI, marked diffusion restriction (ADC: ___×10⁻³ mm²/s) in the mass, consistent with aggressive malignancy.
On FDG PET-CT, very intense FDG uptake is seen (SUVmax generally 15-30+). Necrotic areas show low uptake. PET-CT critical for staging and treatment response. Multiorgan involvement (spleen, liver, skin, bone) may be detected.
Report Sentence
FDG PET-CT demonstrates very intense FDG uptake (SUVmax: ___) in the mass; consistent with aggressive histiocytic neoplasm.
On T2, large mass shows heterogeneous signal — viable tumoral area hyperintense, necrosis and hemorrhage areas variable signal. Heterogeneous enhancement on contrast-enhanced T1. Invasion of surrounding structures evaluated.
Report Sentence
On MRI T2, large mass demonstrates heterogeneous signal reflecting coexistence of viable tumoral, necrotic, and hemorrhagic areas.
Criteria
No prior lymphoid neoplasm history. Carries BRAF V600E or MAPK pathway mutations (50%+).
Distinct Features
Vemurafenib/dabrafenib treatment may be considered in BRAF V600E positive cases — targeted therapy option.
Criteria
Prior follicular lymphoma, DLBCL, or ALL history. Shared clonal rearrangement with original lymphoid neoplasm.
Distinct Features
Appears during or after lymphoid neoplasm treatment. Two neoplasms may coexist (composite). Worse prognosis.
Criteria
HLH findings with HS — fever, hepatosplenomegaly, pancytopenia, hypertriglyceridemia, hypofibrinogenemia, elevated ferritin.
Distinct Features
Worst prognosis. Hepatosplenomegaly dominant on CT. Hemophagocytosis in bone marrow. Requires emergent treatment.
Distinguishing Feature
DLBCL may show similar aggressive appearance but is CD20+/CD68-; HS is CD68+/CD163+/CD20-. Hemophagocytic syndrome more commonly accompanies HS. Definitive differentiation by immunohistochemistry.
Distinguishing Feature
In metastatic adenocarcinoma there is usually known primary tumor history; HS is primary histiocytic neoplasm. CK+/CD68- in adenocarcinoma while CK-/CD68+ in HS. Hemophagocytic syndrome may accompany HS.
Distinguishing Feature
In Rosai-Dorfman S100+/CD68+ histiocytes show emperipolesis and disease is benign; in HS malignant histiocytes do not show emperipolesis and disease is aggressive. RD shows homogeneous enhancement without necrosis; HS shows heterogeneous enhancement with necrosis.
Distinguishing Feature
In HL mediastinal involvement predominates and Reed-Sternberg cells CD30+/CD15+/CD68-; in HS CD68+/CD163+/CD30- and mediastinal predominance not expected. HS shows more aggressive course.
Urgency
emergentManagement
medicalBiopsy
NeededFollow-up
3-monthHistiocytic sarcoma is a rare and aggressive neoplasm requiring emergent treatment. Diagnosis by biopsy — CD68+, CD163+, lysozyme+ immunophenotype is diagnostic. BRAF V600E mutation should be tested (targeted therapy option). No standard chemotherapy regimen — CHOP, ICE, or etoposide-based regimens used. Vemurafenib/dabrafenib may be effective in BRAF V600E+ cases. If hemophagocytic syndrome accompanies, HLH protocol (etoposide+dexamethasone) added. Prognosis is poor — median survival 12-24 months for localized, 6-12 months for disseminated disease. PET-CT critical for treatment response monitoring.
Histiocytic sarcoma is an extremely aggressive neoplasm with poor prognosis (median survival 6-12 months). No standard treatment protocol exists — CHOP-like regimens, salvage regimens such as ICE or DHAP have been tried. Surgery plus or minus radiotherapy may benefit localized disease. Allogeneic stem cell transplantation may be considered in refractory cases. Development of hemophagocytic syndrome requires urgent intervention.